In case of isolation from a nonsterile site, the pathogen had to be considered clinically pathogenic

In case of isolation from a nonsterile site, the pathogen had to be considered clinically pathogenic. the 4.5 mg/kg dose is superior to the 7.5 mg/kg dose was found to be 0.94, and the next 10 patients were each assigned to the ATG 4.5 mg/kg arm. The posterior mean treatment success rates for the ATG 4.5 mg/kg and ATG 7.5 mg/kg arms were 0.73 and 0.45, respectively. The posterior probability that the success rate was greater in the 4.5 mg/kg arm than in the 7.5 mg/kg arm was 0.93. There was no difference in the overall survival (p=0.607), relapse-free survival (p=0.607), treatment-related mortality Phenoxodiol (p=0.131), or incidence of acute (p=0.303) Phenoxodiol or chronic GVHD (p=0.999) between the two doses. ATG levels were not associated with clinical outcomes. Thus, our results favor the use of ATG 4.5 mg/kg over ATG 7.5 mg/kg in patients undergoing unrelated donor HCT with RIC regimens. Keywords:ATG, Graft-Versus-Host Disease, hematopoietic cell transplantation == Introduction == Rabbit antithymocyte globulin (ATG) (Genzyme Co., Cambridge, MA) has been increasingly utilized for the prevention of graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT).[1]The mechanism of action is multifaceted and involves T-cell depletion in the blood and lymphoid tissues;[2]apoptosis of nave B cells, activated B cells, and plasma cells;[3,4]and enrichment of regulatory T cells and natural killer cells.[5]Randomized trials have shown that ATG use can decrease the incidence of acute (a) and chronic (c) GVHD after allogeneic HCT, however a survival benefit is generally not seen.[6,7] In the study by Finke et al, who compared rabbit anti-Jurkat ATG-Fresenius (ATG-F; Fresenius Biotech, Graefelfing, Germany) versus no ATG in patients undergoing unrelated donor allogeneic HCT, the cumulative Phenoxodiol incidence of grade II-IV aGVHD in the ATG-F group was 33% (95% CI 25.143.5) versus 51% (95% CI 42.061.9) in the control group (p=0.011). The 2-12 months cumulative incidence Phenoxodiol of considerable cGVHD in the ATG-F group was 12.2% (95% CI 7.021.3) versus 42.6% (95% CI 33.055.0) in the control group (p=<0.0001). Despite the decrease in the incidence of GVHD, the 2-12 months cumulative incidence of non-relapse mortality (NRM) was not statistically different between the two groups [(ATG-F group 19.6% (95% CI 13.229.0) versus 28.9% (95% CI 20.840.1) in the control group (p=0.20)]. The 2-12 months disease-free survival (DFS) rate [(ATG-F group 51.6% (95% CI 41.861.4) versus control group 47.5% (95% CI 37.157.9) p=0.65] and the overall survival (OS) rate [ATG-F group 59.2% (95% CI 49.568.9), versus control group 51.9% (41.362.5) p=0.47] were also not significantly different between the two arms.[6]In another study, Bacigalupo et al. reported the results of 2 consecutive randomized trials that compared rabbit ATG (Sangstat, Lyon, France) to no ATG in patients undergoing unrelated donor allogeneic HCT.[7]Grade II-IV aGVHD was diagnosed in 72% of patients in the ATG arm versus 69% (P=0.6) in the first and in 37% of patients in the ATG-arm versus 79% (P=0.001) in the second trial. Overall, considerable cGVHD developed more frequently in patients given no ATG (62% vs. 39%; p=.04). The actuarial event-free survival at 2-years in patients IL22 antibody who did and did not receive ATG was 34% and 20%, respectively in the first trial (p=0.6) and 17% versus 15% (p=0.8), respectively in the second trial. The actuarial survival rates between the ATG and no ATG arms were 55% and 56% (p=0.8), respectively in the first trial and 43% in each arm in the second trial. On the other hand, in a prospective randomized study by Champlin et al., no difference in the probability of grade II-IV aGVHD at day 100 [18% (95% CI 10%29%) versus 11% (95% CI 6%22%)] and cGVHD at 5 years [21% (95% CI 12%33%) versus 32% (95% CI 21%44%)] were seen between the no ATG and the equine ATG arm (ATGAM; Upjohn, Kalamazoo, MI; or Lymphoglobulin Merieux, Laboratories Pasteur Merieux, Lyon, France), respectively.[8] The optimal dose of ATG in the setting of reduced-intensity conditioning (RIC) allogeneic HCT is not clearly known. While effective in preventing GVHD, higher doses of ATG (>10 mg/kg) may be associated with higher prices of infection and perhaps higher treatment-related mortality (TRM) than lower dosages of ATG or no ATG.[6,7,9,10]The threat of fatal infections was higher in the high-dose ATG arm (15 mg/kg) than in the no ATG arm in the analysis by Bacigalupo et al.[7] as the hazards of infection with cytomegalovirus or herpes virus and of Epstein-Barr viruspositive post-transplant lymphoproliferative disorder had been higher in the ATG-F (20 mg/kg) arm than in the no ATG arm in the analysis by Finke et al.[6] Here we sought to optimize the usage of rabbit ATG in the environment of unrelated donor (UD) RIC allogeneic HCT. We suggested to evaluate the protection and effectiveness of two low to intermediate dosage degrees of rabbit ATG (4.5 mg/kg and 7.5.